Peripheral T-Cell Lymphoma, Not Otherwise Specified Clinical Trials

17 clinical trials for Peripheral T-Cell Lymphoma, Not Otherwise Specified across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas — RECRUITING · PHASE2
• Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy — RECRUITING · PHASE3
• Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma — RECRUITING · PHASE1
• Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas — RECRUITING · PHASE1
• A Registry for People With T-cell Lymphoma — RECRUITING
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma — RECRUITING · PHASE3
• Q702 for the Treatment of Patients With Hematologic Malignancies — RECRUITING · PHASE1
• Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma — SUSPENDED · PHASE2
• Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency — ACTIVE_NOT_RECRUITING · NA
• Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma — TERMINATED · PHASE1
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms — COMPLETED · PHASE2
• Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma — COMPLETED · PHASE1
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. — OTHER · NA
• CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL — OTHER · PHASE2
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• Risk Stratification of Nodal PTCL — COMPLETED

Refine this search